Oncology team extends presence in the treatment pathway using epidemiology and claims data analysis

Publish date: 28 Jun, 2018

Challenge

The oncology team at a large pharmaceutical company was looking to optimize market position on several fronts:


  • Defend its territory as a first-line therapy for indication #1
  • Uncover opportunities to optimize its place in the treatment pathway for indication #2
  • Plan a successful launch strategy for indication #3

To achieve this, the company would need to evaluate the threats and opportunities in the therapy landscape for all three indications.

It would also require a deeper understanding of the patient population and the unmet needs, to inform and develop its strategy.

Solution


DRG’s experts used a combination of claims data and epidemiology data to build a robust picture of the therapeutic landscape and patient journeys for the three indications.

Key analyses:

  • Market shares of current approved treatments
  • Switch patterns for key lines of therapy, including treatment durations
  • Market size and patient characteristics, including demographics and co-morbidities
  • Unmet needs in the treatment landscape

Elements of success


  • Real-world data: U.S. pharmacy and claims data
  • DRG expertise: Oncology experts, data scientists, and epidemiologists
  • Primary and secondary research
  • Integrated analysis

Results

DRG delivered custom reports of the therapy landscape and the patient journeys for the three indications. This provided the client with the tools and information needed to build a roadmap and optimize market position.

Significance for client

The client was empowered to make confident planning decisions around:


  • Positioning its drug for increased market share
  • Mitigating drug-switching threats


 

 

 

 

 

 

 

 

 

Source: DRG Real World Data Repository

Learn more about how our real-world data capabilities can provide the evidence you need to develop effective business strategies.


 

Download PDF

 



 

Case Study: Oncology Clinical Trial Monitor

NEXT ARTICLE